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Abstract
Genotype-to-phenotype correlation studies in myotonic dystrophy type 1 (DM1) have been
confounded by the age-dependent, tissue-specific and expansion-biased features of
somatic mosaicism of the expanded CTG repeat. Previously, we showed that by controlling
for the confounding effects of somatic instability to estimate the progenitor allele CTG length
in blood DNA, age at onset correlations could be significantly improved. To determine the
suitability of saliva DNA as a source for genotyping, we used small pool-PCR to perform a
detailed quantitative study of the somatic mutational dynamics of the CTG repeat in saliva
and blood DNA from 40 DM1 patients. Notably, the modal allele length in saliva was only
moderately higher in saliva and not as large as previously observed in most other tissues.
The lower boundary of the allele distribution was also slightly higher in saliva than it was in
blood DNA. However, the progenitor allele length estimated in blood explained more of the
variation in age at onset than that estimated from saliva. Interestingly, although the modal
allele length was slightly higher in saliva, the overall degree of somatic variation was typi-
cally lower than in blood DNA, revealing new insights into the tissue-specific dynamics of
somatic mosaicism. These data indicate that saliva constitutes an accessible, non-invasive
and suitable DNA sample source for performing genetic studies in DM1.
Introduction
Myotonic dystrophy type 1 (DM1) is the most common dominantly inherited myopathy in
adults. It is a progressive and disabling disease that shows a highly variable phenotype, both in
severity and clinical manifestations. The main symptoms include myotonia, muscle wasting
and weakness, cardiac problems, cataracts, somnolence, cognitive dysfunction and behavioral
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abnormalities [1, 2]. The disease is caused by the expansion of an unstable trinucleotide
(CTG)n repeat, located in the 3’-untranslated region (3’-UTR) of the DM protein kinase
(DMPK) gene [3–5]. Non-DM1 individuals in the general population usually carry between 5
to 37 CTG repeats, while individuals with DM1 inherit from 50 to several thousand CTG
repeats [3]. Above 50 CTGs the repeat becomes highly unstable, both in the germ line and
somatic tissues [6, 7].
Somatic mosaicism of the expanded CTG repeat first became evident on autoradiographs
obtained from Southern blot hybridization of restriction-digested genomic blood DNA. Smears
instead of discrete bands were observed for the expanded alleles in DM1 patients, representing
a collection of cells in the same tissue containing different repeat lengths [3, 4, 8]. For this rea-
son, it was common practice to measure the midpoint of the smear and use this allele size in
clinical correlations (genotype to phenotype). Although this allele size correlates positively with
the severity of the disease and negatively with the age of onset of symptoms, these correlations
typically remained poor, explaining less than 50% of the variation in age of onset [9–12].
Failure to reveal accurate clinical correlations in DM1 could be explained by omission to
take into account some particular features of the somatic instability (SI), such as the tissue-,
age- and allele length-dependence [13–17]; features that very likely contribute to the age of
onset and the progressive nature of the disease. In order to control for some of these confound-
ing effects of SI and to improve the clinical correlations in DM1, we previously used small
pool-PCR (SP-PCR) to estimate the progenitor allele length (PAL i.e. the allele size transmitted
by the affected parent to the affected offspring) in blood DNA. Results from these studies
clearly indicate that the estimated PAL (ePAL) is the major modifier of the age of onset of the
DM1, explaining more than 70% of the variation in age of onset. SP-PCR was also used to mea-
sure the degree of SI, showing that the residual variation in SI, not accounted for by PAL and
age, also contributes towards disease progression [16, 18].
The study of multiple tissues from the same DM1 patients has revealed the presence of dif-
ferent modal repeat sizes between tissues. Notably, much larger expanded alleles are observed
in skeletal muscle (the main affected tissue in DM1) than in the blood of DM1 patients [19–
21]. It was initially thought that age at onset correlations would improve by using the allele size
measured in skeletal muscle. Surprisingly though, age at onset correlations in skeletal muscle
DNA were poorer than those obtained with blood DNA [21]. These data suggest that the con-
founding effects of somatic mosaicism are greater in muscle than they are in blood.
Here, by using SP-PCR and by comparing with peripheral blood lymphocytes (PBL), we
explore the suitability of using saliva to perform the molecular diagnosis and establish age at
onset correlations in DM1 through a less invasive method. Several advantages of using saliva
over blood as the source of DNA for genetic studies have been described, including the ease
and speed of collection, lower cost, non-invasive nature with no counter-indications [22], ease
of storage and shipment, and lack of clotting [23, 24]. Because saliva collection does not
involve the use of needles, it is overall more comfortable for patients [25] and more patients
are willing to participate in research [26]. It is worth noting that DNA and RNA extracted
from saliva has been used for many large studies, including analyses of cancer, metabolic dis-
ease, infectious disease, sports medicine, drug abuse, orthodontics, and even proteomic, tran-
scriptomic and metabolomic studies (reviewed in [25]).
Material and methods
Study population
Peripheral blood and saliva samples were collected simultaneously from 40 Costa Rican DM1
patients (21 women and 19 men): three late-onset cases, 31 classic adult-onset cases, three
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juvenile-onset cases, two congenital-onset cases and one carrier subject who was asymptomatic
at sampling. The DM1 population has already been well characterized and the age of onset has
been previously recorded and reported [16, 18]. Age of onset was based on the detection of
physical myotonia (grip myotonia), muscle weakness and/or the presence of cataracts. Age of
onset was recorded after clinical evaluation by one of four different experienced neurologists,
or after an interview by the same neurologists or by one of two different experienced clinical
geneticists.
For saliva collection, in order to increase the fraction of buccal epithelium cells recovered,
the patients were requested to carefully wipe the inner side of their cheeks with their tongue
and spit in a collection tube until obtaining ~5 ml of saliva. Simultaneously, 10 ml of peripheral
blood was drawn into EDTA-containing vacutainer tubes. DNA was isolated by proteinase K/
phenol-chloroform extraction and quantified by optical density at 260 nm in a NanoDrop
spectrophotometer (Thermo Scientific, USA) and stored at -20˚C. The Scientific-Ethics Com-
mittee of the Universidad de Costa Rica approved the project. All samples were collected after
obtaining written informed consent in accordance with the protocols approved by the Scien-
tific-Ethics Committee of the Universidad de Costa Rica.
Molecular analysis
Measuring ePAL and degree of somatic instability. To estimate the PAL and determine
the degree of SI in each sample, we used SP-PCR as previously described [15, 16]. Briefly, for
estimating PAL, we performed five reactions per sample with ~200 to 300 pg of input DNA
and the PCR products were hybridized with a (CTG)66 radiolabeled probe. The PAL was esti-
mated as the approximate lower boundary of the total allele distribution obtained for each
sample [16, 18].
In order to carry out a detailed quantitative analysis of somatic mosaicism, we used single
molecule SP-PCR (using 10 to 70 pg of input DNA per reaction) to measure at least 50 single
molecules per sample per patient. The degree of SI was defined as the difference between the
10th and 90th percentile of the total allele distribution as described previously [16, 18]. SP-PCR
products were detected by radioactive Southern blot hybridization and sized using UVIband-
map software (UVITEC, UK).
Screening for variant repeats. Previously described methods [27] were followed in
order to identify the presence or absence of AciI sensitive variant repeats in the Costa Rican
DM1 samples. Briefly, we carried out two PCRs per sample using 400 to 500 pg of input
DNA followed by an AciI restriction digestion according to instructions provided by the
manufacturer (New England Biolabs, USA). Through this approach, we were be able to
exclude the most commonly observed CGG and CCG variant repeats within the CTG repeat
expansion, but this does not exclude the presence of other variant repeats type in the samples
analysed in this study. Digested and undigested PCR products were resolved by agarose
gel electrophoresis and detected by Southern blot hybridization. A positive variant repeat
sample was analysed in each experiment to confirm the presence or absence of variant repeats
in the samples under investigation. The structure of the positive variant repeat allele is
~(CTG)225(CCG)1(CTG)1(CCG)1(CTG)4(CCG)1(CTG)1(CCG)1(CTG)1(CCG)2(CTG)1
(CCG)1(CTG)1(CCG)1(CTG)23.
DNA methylation analyses of CTCF binding sites. Analysis of DNA methylation levels
in two CTCF binding sites flanking the (CTG)n repeat at the DMPK locus was carried out through
PyroMethA technique (Pyrosequencing-based Methylation Analysis or PMA). The assays
employed were designed to interrogate 11 CpG sites upstream of the CTG repeat (six within the
first CTCF-binding site, ‘CTCF1’), and six CpG sites downstream of the CTG repeat (three within
Saliva and somatic instability in myotonic dystrophy type 1
PLOS ONE | https://doi.org/10.1371/journal.pone.0216407 May 2, 2019 3 / 17
the second CTCF-binding site, ‘CTCF2’) [28, 29]. Firstly, 300 ng of DNA from each sample was
subjected to sodium-bisulfite treatment using the EZ DNA Methylation-Gold kit (Zymo
Research, USA), according to instructions provided by the manufacturer. This treatment converts
unmethylated cytosines to uracils, while leaving 5-methylcytosines (5-mC) unaffected. The pres-
ence of cytosine residues (as indicative of methylation) flanking the CTG repeat expansion was
later detected quantitatively through pyrosequencing. Oligonucleotides required for this purpose
were custom designed using the PyroMarkQ Assay Design software 1.0 (Biotage, USA) and opti-
mized accordingly (see S1 Table for complete list of primers used in this study).
Briefly, PCR amplification of 15 ng of bisulfite treated-DNA was carried out in a final reac-
tion volume of 25 μl, containing 1X Hot StarTaq Master Mix (Qiagen, Germany), 100 pmol of
gene-specific forward primer (either PS-DMPK-F3 for CTCF1, or PS-DMPK-F4 for CTCF2),
10 pmol of gene-specific reverse primer (either PS-U2-DMPK-R3 for CTCF1, or PS-U2-
DMPK-R4 for CTCF2) and 90 pmol of biotinylated universal primer (PS-Bio-UNIV2). Ampli-
fication was performed with a denaturing step of 5 min at 95˚C, followed by 45 cycles of dena-
turing for 30 s at 95˚C, annealing for 1 min at 51˚C for CTCF1 or 50˚C for CTCF2, and
extension for 45 s at 72˚C. A final extension step was performed at 72˚C for 7 min.
Amplified PCR products (8 μl) were combined with 2 μl streptavidin sepharose high-per-
formance beads (GE Healthcare, UK), 40 μl of binding buffer (Biotage, USA) and 30 μl of
MilliQ water, and subjected to single-strand isolation of the biotinylated template using the
PyroMark Vacuum Prep WorkStation (Biotage, USA) as instructed by the manufacturer. Iso-
lated products were dispensed into optical plates containing 12 μl of the corresponding
sequencing primer (either PS-DMPK-S3 for CTCF1, or PS-DMPK-S4 for CTCF2) dissolved in
annealing buffer (Biotage, USA) to a final concentration of 0.4 μM. To allow annealing of the
sequencing primer to the template, plates were incubated for 5 min in a heating block at 85˚C,
left to cool for 5 min and then placed at room temperature for 5 min.
Pyrosequencing was carried out using the PSQ96 HS platform (Biotage, USA) and Pyro-
Mark Gold Q96 reagents (Biotage, USA) according to the manufacturer’s instructions and
analysed with Q-CpG software (Biotage, USA), which estimates the methylation percentage
for each of the interrogated CpG sites. The average methylation value of for all CpG sites ana-
lysed in each assay was calculated and the CTCF-binding sites were considered to be methyl-
ated when this value was higher than 10% [30].
Statistical analysis
Paired sample t-tests were carried out in SPSS Statistics 19 (IBM, USA) in order to compare
ePAL and SI among the two different sample sources, whereas single and multiple linear
regressions were used to identify the major modifiers of the age of onset and the degree of SI
of each tissue. Frequency curves from total allele distributions were compared through Ander-
son-Darling (AD) testing, using the kSamples 1.2–4 package for R.
Results
ePAL measured from saliva samples can be used for clinical correlations in
DM1
By using SP-PCR we were able to amplify in all of the DM1 samples the expanded CTG allele
in both blood and saliva DNA (Fig 1). We observed that the modal allele length measured in
both tissues was highly correlated (r = 0.879, n = 38, p< 0.001, Fig 2A) and that in saliva, it
was typically a little bit larger than in blood (mean modal allele in blood = 486 repeats;
saliva = 529 repeats; t = -1.74, df = 37, p = 0.090, Figs 1, 2A and 2D and data in S1A Fig).
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Interestingly, we identified two individuals who presented with a small non-disease associ-
ated allele (< 50 repeats) and two additional clear expanded alleles in the two tissue sources
analysed (� 50 repeats). These patients showed the typical adult-onset form of the disease. The
presence of two expanded alleles is assumed to reflect an early embryonic mutation event [31,
32], and because of the difficulty in defining the ePAL or assigning somatic variants to the
appropriate allele in such individuals, these two cases were excluded from further analysis.
Previously, we estimated the PAL as the lower boundary of the allele distribution after per-
forming SP-PCR with 200 to 300 pg of input DNA obtained from peripheral blood [16, 18].
Here, by using the same approach, we investigated if the lower boundary observed in PBL
DNA was conserved in DNA derived from saliva collected at the same point in time. The PAL
was estimated from both tissue sources in 40 DM1 patients (80 samples in total). We observed
that blood and saliva ePALs were highly correlated (r = 0.908, n = 38, p< 0.001, Fig 2B). In
general, the ePAL was larger in saliva than in blood (mean ePAL in blood = 310 repeats;
saliva = 414 repeats; t = -5.32, df = 37, p< 0.001, Figs 1, 2B and 2D and data in S1B Fig, data in
S2 Table). This difference was most evident in patients with ePALs larger than 150 CTGs for
whom only one patient showed a larger ePAL from blood than saliva DNA. When the ePAL
was smaller than 150 CTG repeats, the lower boundaries of the distribution of expanded
alleles, and therefore the ePALs, in DNA from the two tissue sources were very closely
conserved.
With the aim of determining which sample source might be more suitable for establishing
genotype to phenotype correlations in DM1, we explored the relationship between ePAL and
age at onset of symptoms. One mutation carrier was excluded from these analyses, as he
remained asymptomatic at the time of sampling. Linear regression models showed that the
logarithm of PAL estimated in blood DNA explained 75% of the variation in age at onset,
whereas the logarithm of PAL estimated in saliva DNA accounted for only 66% of the variation
in age of onset (Model 1, Table 1). This analysis did not reveal a significant difference (Fisher r
to z transformation, z = -0.73, p = 0.465) in the coefficients of determination between blood (r2
= 0.748, n = 37) and saliva (r2 = 0.661, n = 37). A previous study has suggested the presence of
additional nonlinear components in the regression models of age of onset and the size of the
Fig 1. Representative autoradiographs of SP-PCR for progenitor allele estimation (ePAL) in four DM1 patients using two different DNA sources (left
blood and right saliva). The lower boundary of the allele distribution in each tissue was used to estimate the PAL. The bottom arrowhead indicates the PAL
estimated in blood. In patients with blood ePAL< 150 CTG repeats (CR317 and CR145), the estimation of PAL using saliva was about the same, but in patients
with an ePAL> 150 CTG repeats (CR333 and CR183) the ePAL measured in saliva was larger than in blood. The top arrowhead indicates the modal allele
length for each tissue. For each sample, we indicate the ePAL measured in blood (ePAL), the age at sampling (Ages) and the age of onset (Ageo). The molecular
weight marker sizes are shown converted to CTG repeat numbers.
https://doi.org/10.1371/journal.pone.0216407.g001
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Fig 2. Comparison of the modal allele size, progenitor allele length (ePAL), and degree of somatic instability (SI) from two different
DNA tissue sources of the same DM1 patient. Panel A shows the comparison of the modal allele length in the two tissues analysed. The
dashed line corresponds to the line of best for the correlation. Points above the solid line indicate larger modal allele length in saliva than in
blood. Panel B shows the comparison of the ePAL in the two tissues analysed. The dashed line corresponds to the line of best fit for the
correlation. Points above the solid line indicate larger ePALs in saliva than in blood. Panel C shows the comparison of the degree of SI in
Saliva and somatic instability in myotonic dystrophy type 1
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ePAL [16]. Thus, we included a quadratic component into the model, but this did not lead to
any significant improvement (Model 2, Table 1). Given that the modal allele length in saliva
DNA was greater than that observed in blood, it suggests that the net average rate of expansion
is greater in saliva than in blood. Likewise, the larger PAL estimated from saliva also suggests
that the lower boundary has increased more rapidly in this tissue. This interpretation is consis-
tent with the greater explanatory power of blood ePAL in defining genotype to phenotype cor-
relations and suggests the PAL estimated from blood is likely to be closer to the true PAL than
that estimated from saliva.
The behavior of the (CTG)n repeat expansion shows subtle differences
among saliva and blood cells in DM1 patients
In order to perform a more detailed quantitative analysis of SI in blood and saliva DNA, we
carried out single molecule SP-PCR in 38 DM1 patients. We sized a total of 12,488 mutant
alleles with an average of 164 (± 67) molecules per sample (data in S2 Table). The degree of SI
(defined as the difference between the 10th and 90th percentile of the total allele distribution)
was calculated for each sample. As with the ePAL, the degree of SI measured from both DNA
sources was highly correlated (r = 0.667, n = 38, p< 0.001, Fig 2C.). Interestingly, excluding
the two congenital cases (CDM) in our study, which showed a clearly different SI pattern (Fig
3), we observed a higher degree of SI in peripheral blood than in saliva (mean SI in
blood = 329 repeats; saliva = 250 repeats; t = 5.39, df = 35, p< 0.001, Fig 2C and 2D and data
in S1C Fig).
By investigating the total allele distributions in DM1 patients with small CTG expansions
(< 150 CTG repeats in blood ePAL), we observed that in most of the DM1 patients, both cell
sources showed similar allele distributions with a positive asymmetry (Fig 3). However, in
non-congenital patients with larger alleles (> 150 CTG repeats in blood ePAL), the mutant
allele distributions tended to be more symmetrical, being wider for peripheral blood than for
the two tissues analysed. The dashed line corresponds to the line of best fit for the correlation. Points below the solid line indicate a lower
degree of SI in saliva than in blood. Panels in D show a diagrammatic comparison of the somatic instability degree (SI) and the estimated
progenitor allele length (ePAL) from two different DNA sources of the 38 DM1 patients analysed in this project. The whiskers represent
the SI range for each tissue of each patient, whereas the diamonds and triangles indicate the modal allele in saliva and blood respectively.
For better comparison, samples were split over three graphs according to the ePAL measured in blood.
https://doi.org/10.1371/journal.pone.0216407.g002
Table 1. Regression models of the relationship between age at onset (Ageo) and the progenitor allele length (ePAL) estimated from two different DNA tissue sources
of the same DM1 patient.
Model Source Adjusted r2 p Parameter Coefficient Standard error t-statistic p
Model 1: Ageo = β0 + β1 log(ePAL)
n = 37 individuals
Blood 0.748 <0.001 Intercept β0 121.07 9.28 13.05 <0.001
log(ePAL) β1 -39.83 3.84 -10.38 <0.001
Saliva 0.661 <0.001 Intercept β0 108.52 9.93 10.93 <0.001
log(ePAL) β1 -33.07 3.92 -8.44 <0.001
Model 2: Ageo = β0 + β1 log(ePAL) + β2 log(ePAL)
2
n = 37 individuals
Blood 0.753 <0.001 Intercept β0 217.28 74.63 2.91 0.006
log(ePAL) β1 -122.69 63.89 -1.92 0.063
log(ePAL)2 β2 17.53 13.49 1.30 0.203
Saliva 0.668 <0.001 Intercept β0 208.38 76.32 2.73 0.010
log(ePAL) β1 -117.87 64.39 -1.83 0.076
log(ePAL)2 β2 17.59 13.33 1.32 0.196
The table shows the squared coefficient of correlation (r2) and statistical significance (p) for each model, and the coefficient, standard error, t-statistic and statistical
significance (p) associated with each parameter in the model. The number of individuals used in each analysis is indicated (n).
https://doi.org/10.1371/journal.pone.0216407.t001
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saliva cells and, therefore, with the latter distribution immersed within the former (Fig 3). Dif-
ferences in the boundaries of the total allele distributions were compared (taking the 10th per-
centile as the lower boundary and the 90th percentile as the upper boundary), and we found
that allele distributions in blood and saliva differed to a greater extent in their lower end than
in the upper end (mean size difference between the lower boundary = 104.4; upper bound-
ary = 41.9; t = 2.67, df = 37, p = 0.011, data in S2A Fig).
Fig 3. Representative histograms showing the allele distributions in two tissue sources of six DM1 patients. The header indicates the progenitor allele
length estimated in blood (ePAL) for each patient and the probability value (p) of equal distributions in both sample sources, calculated using the t-statistic of
Anderson-Darling (AD). Patients with blood ePAL< 150 CTG repeats show similar allele distributions, while non-congenital DM1 patients with an
ePAL> 150 CTG repeats showed a higher degree of instability in blood. Congenital cases showed higher levels of instability in saliva than in blood (bottom
right).
https://doi.org/10.1371/journal.pone.0216407.g003
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In order to analyze and compare the major modifiers of SI in the two DNA sources under
study, we ran a multivariate regression model that has been previously used for this purpose
[16, 18]. As the ePAL measured in blood was considered as the best estimative of the actual
PAL, we therefore, used it in the saliva and blood SI models (Table 2). As expected, more than
85% of the SI variation in blood DNA from DM1 patients was explained by a complex syner-
gistic relationship between the ePAL and age at sampling, whereas for DNA obtained from
saliva, the same model explained about 72% of the variation in SI (Table 2; data in S2B Fig),
suggesting that other unidentified tissue-specific factors, such as relative DNA repair gene
expression levels, might be acting as modifiers of the behavior of the CTG repeats in buccal
cells.
Neither variant repeats nor methylation levels act as modifiers of SI in the
tissues analysed
We next determined the presence or absence of variant repeats (CGG and CCG) within the
DM1 (CTG)n repeat and analysed the methylation levels of two CTCF-binging sites flanking
the CTG repeat, in order to determine if cis-acting modifiers might account for the subtle dif-
ferences found in the behavior of the CTG repeats between the two tissues [27–29, 33]. The
relationship between methylation and SI in DM1 is not yet clear and the presence of variant
repeats have been associated with a stabilization of the CTG repeat, which might help to
explain the differences we found. However, no CGG or CCG variant repeats were detected in
the DNA from blood or saliva in the 38 DM1 patients analysed in this study. This does not
exclude the possibility of other rarer variant repeats in these samples. Regarding the methyla-
tion study, we considered the DNA samples to be methylated only if the mean methylation of
all of the CpGs analysed were� 10%, as measured methylation levels below 10% are consid-
ered unreliable [30]. We only detected moderate methylation levels (between 10 to 50%)
upstream of the CTG repeat (CTCF1 site) in one of the two CDM cases (being higher in blood
than in saliva). Similarly, moderate levels of methylation downstream of the CTG repeat
Table 2. Regression models of the relationship between somatic instability (SI) in DNA observed in blood and saliva and the estimated progenitor allele length in
blood (ePAL) and the age at sampling (Ages).
Model Source Adjusted
r2








n = 38 individuals
Blood 0.859 <0.001 Intercept β0 -28.054 6.599 -4.251 <0.001
log(ePAL) β1 21.444 4.404 4.869 <0.001
Ages β2 0.179 0.077 2.314 0.027
log(ePAL) �
Ages
β3 -0.049 0.024 -2.012 0.053
log(ePAL)2 β4 -3.825 0.744 -5.139 <0.001
Ages
2 β5 -0.001 0.000 -2.543 0.016
Saliva 0.717 <0.001 Intercept β0 -27.687 8.743 -3.167 0.003
log(ePAL) β1 20.471 5.834 3.509 0.001
Ages β2 0.224 0.102 2.196 0.035
log(ePAL) �
Ages
β3 -0.068 0.032 -2.120 0.042
log(ePAL)2 β4 -3.493 0.986 -3.542 0.001
Ages β5 -0.001 0.000 -2.080 0.046
The table shows the squared coefficient of correlation (r2) and statistical significance (p) for each tissue, and the coefficient, standard error, t-statistic and statistical
significance (p) associated with each parameter in the model. The number of individuals used in the analysis is indicated (n).
https://doi.org/10.1371/journal.pone.0216407.t002
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(CTCF2) were also only detected in the two CDM cases analysed in this project and only in
blood DNA (Table 3). All the remaining patients showed mean methylation levels in the two
analysed CTCF-binding sites lower than 10% in both tissue sources.
Discussion
By using Southern blot hybridization of restriction digested genomic DNA from blood, it is
possible to measure the modal allele length in blood DNA from DM1 patients. Despite the fact
that the allele size thus determined shows a highly significant negative correlation with age of
onset, this allele size explains less than 50% of the variation in age of onset [8–10, 12, 34, 35].
We previously demonstrated that these poor correlations are due to the confounding effects of
somatic expansion and that by using the ePAL, these clinical correlations could be improved
[16, 18]. Notably, the modal allele size measured in skeletal muscle is typically much larger
than that observed in blood DNA [19–21]. This observation is consistent with a causal role for
somatic expansions driving the tissue specificity of the symptoms. However, repeat lengths in
skeletal muscle are usually so large that they cannot be efficiently PCR amplified and need to
be measured using Southern blot hybridization of restriction digested genomic DNA. More-
over, modal allele length in muscle provides even poorer age at onset correlations than
observed with blood DNA [21]. Again, this can be interpreted as a confounding effect of
somatic expansion in driving the modal allele length even further from the PAL in muscle.
Thus, other tissues in which the repeat is relatively stable might also be suitable for diagnostic
purposes. However, it appears that nearly all other tissues previously assessed in DM1, also
contain large somatically acquired expansions [13]. Notably though, the DM1 repeat expan-
sion in cerebellum appears to be even more stable than in blood [29, 36], raising the possibility
that estimating the PAL in cerebellum could provide even better genotype to phenotype corre-
lations in DM1. However, cerebellum is not an accessible tissue for performing genetic analy-
ses in DM1 patients. Here, we have revealed that the degree of somatic mosaicism of the
expanded CTG repeat in saliva is broadly comparable to that observed in blood DNA and thus
represents an excellent source of DNA for genetic studies in DM1. During the initial review of
this manuscript, Pesovic et. al. [37] characterized the mutational dynamics of the CTG repeat
in blood and buccal cells in a small number of DM1 patients carrying variant repeats in both
tissues. They described some features that we also found in our larger cohort: specifically, the
progenitor allele length was higher and the levels of somatic instability were lower in buccal
cells than in blood, with some differences in the CTG mutational dynamics between both tis-
sues, but with overall much more slower dynamics, triggered by the presence of variant repeats
that confers stability to the CTG repeat tract [27, 33]. Obtaining saliva DNA is a much less
invasive method than phlebotomy, being of great benefit especially for those patients with fear
of needles. This situation could be particularly relevant in children with autism-like symptoms,
Table 3. Mean methylation percentage in blood and saliva of congenital cases within two CTCF binding sites.
Site Sample Mean methylation (%)
Blood Saliva
CTCF1 CR179 35.92 12.24
CR189 5.47 5.77
CTCF2 CR179 14.90 2.48
CR189 12.26 6.28
A total of 11 and 6 CpG sites were analysed for the first (CTCF1) and second (CTCF2) binding sites respectively.
Italicized numerals highlight methylated regions. Methylation levels below 10% were considered as baseline levels.
https://doi.org/10.1371/journal.pone.0216407.t003
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as commonly encountered in juvenile and congenital DM1 cases [1, 2]. Furthermore, saliva
has been widely used for carrying out large population screening studies, a study that could be
conducted in DM1 now that we have established the mutational behavior and spectrum of the
CTG repeat in saliva, and the justification for which increases as we move toward the delivery
of novel therapies.
Previously, it was shown that the lower boundary of the total allele distributions obtained
through SP-PCR were conserved over time and between different tissues [15]. In agreement
with this, the PALs estimated from the two analysed tissues were highly correlated in our sam-
ple set, with very similar lower boundaries in patients with ePAL< 150 CTG repeats. How-
ever, we observed that, though correlated, the boundaries were no longer conserved above 150
repeats, where the PAL estimation was consistently higher when analyzing saliva. This suggests
that these differences have arisen from tissue-specific mutational dynamics. Interestingly, the
ePAL from saliva explained about 66% of the variation in the age of onset, which is slightly
lower than the 75% of the variation explained by the ePAL obtained from blood (Table 1).
These data suggest that the PAL estimated from blood more accurately reflects the true PAL.
Nonetheless, the ePAL measured using saliva DNA still provided much better age at onset cor-
relations than the traditional measurement of the midpoint of the smear obtained through
Southern hybridization of blood genomic DNA. Our results thus indicate that saliva could be
an appropriate surrogate for performing genetic analyses in DM1. Similar to Pesovic et. al.
[37], we also used the 10th percentile of the total allele distribution as an estimation of the PAL
as an alternative way for measuring this allele size (data not shown). Although results were
similar between ePAL and the 10th percentile (as an estimation of the PAL) in both tissues,
measuring the 10th percentile of the total allele distribution is more technically challenging,
more time-consuming and more expensive than measuring the ePAL only.
Since it has been previously suggested that CTG•CAG somatic instability starts after the
first three months of embryonic development [38], right after the separation of the germ layers
that give rise to the tissues represented in the sample sources under study (i.e., ectoderm for
buccal epithelium and mesoderm for hematopoietic cells) [39, 40], it is unlikely that the differ-
ences found in the lower boundaries of allele distributions have been caused by an early estab-
lishment of embryonic layers with different sizes of mutated alleles. Most likely, this
phenomenon could be attributed to parameters in the post-natal mutational dynamics of dif-
ferentiated tissues. Interestingly, although saliva showed a higher lower boundary and a higher
modal allele length, PBLs showed higher levels of SI, providing evidence that the mutational
dynamics in different tissues don’t just reflect differences in the absolute rate of expansion.
Previously using a mathematical modelling approach we revealed that the broad repeat length
distributions observed in blood DNA are likely driven by a high frequency of small expansions
and a similarly high frequency of small contractions [41]. It is feasible that in buccal cells there
is a lower rate of contractions relative to expansions. This would cause a greater upward drift
of the lower boundary, but would also result in a narrower range of variants (Fig 4). These
observations might be comparable to observations in Huntington disease (HD) expanded
CAG repeat mouse models, where a wider population of unstable repeats are observed in stria-
tum in comparison to liver, despite a greater increase in mean allele length in liver [42, 43].
Indeed, a previous study found similar results when comparing the DM1 mutation in blood
cells and the HD mutation in buccal epithelium [44]. In this study the estimated mutational
rates, including both expansions and contractions, were significantly lower in HD buccal cells
than in DM1 blood cells, with a lower occurrence of contractions in the former tissue.
Although in this case it is possible that the differences in mutational rates could be attributed
to the different genomic context of the implicated unstable repeats, the authors hypothesized
that the most suitable explanation could be related to cell type rather than disease type.
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The subtle differences observed in the mutational dynamics among tissues might be
accounted for by the effect of different cis- or trans-tissue-specific genetic factors. It is known,
that methylation of CTCF binding sites has been previously associated with increased levels of
instability of the CAG•CTG repeat associated with spinocerebellar ataxia type 7 (SCA7) [45],
and in DM1 methylation seems to vary among tissues, both in humans and transgenic mice
[29]. On the other hand, in some unstable repeat diseases such as SCA1, SCA8 and DM1, the
purity of the respective causal allele has been associated with SI, while variants within the
repetitive tract confer stability to the alleles [27, 33, 46]. In our study, although a higher degree
of SI was observed in blood DNA in comparison to saliva, we observed: 1) that the methylation
levels of the two (CTG)n repeat flanking CTCF binding sites were conserved among the two
sample sources analysed; and, 2) an absence of variant repeats in both of the tissues analysed.
This indicates that these factors likely do not contribute to the subtle differences we observed
in the somatic mutational dynamics among the tissues analysed.
Fig 4. Expansion models of the CTG repeat expansion in blood and saliva. The top model was proposed previously
for the mutational dynamics of the CTG repeat expansion in blood DNA (modified from [15]). Data from this study
suggests that in saliva (lower model), the rate of expansion/contractions is different than in blood, triggering a faster
movement of the lower boundary, a more compact allele distribution and faster progression to a normal distribution
than in blood and with larger modal allele length in saliva with time. In both models, as the number of CTGs increases,
the mean and modal alleles increase and their frequency decreases with time.
https://doi.org/10.1371/journal.pone.0216407.g004
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It should be noted however that the only samples with moderate methylation levels in this
study were the two CDM cases analysed, consistent with previous findings that found that this
DM1 clinical form preferentially showed methylation flanking the CTG repeat expansion [28,
29, 47, 48], and it has been suggested that methylation could be used as a biomarker for CDM
([47], Morales et al, in preparation). The study carried out by Barbe et. al. [47] and this study,
are the only ones that have quantified the levels of methylation flanking the CTG repeat expan-
sion. The difference in the levels of methylation found in both studies could be due to inherent
aspects of the used assay. Despite this, and in agreement with what the Barbe et. al. [47] found,
we also found increased methylation in CDM cases and upstream of the repeat, with one
patient showing higher levels of methylation than the other.
Interestingly, the two CDM cases showed a clearly different SI pattern from that observed
in non-CDM cases, bearing a higher proportion of alleles that have acquired very large con-
tractions in saliva than in PBLs. Previous studies in HD mouse models have provided similar
observations, showing that mice inheriting large mutated alleles (>500 CAG•CTG repeats)
can have a reversion of the expansion/contraction balance in some tissues, with the accumula-
tion of contractions playing an important role in the levels of somatic variation [42]. It remains
to be determined whether the apparent increase in large contractions in congenital patients
could be attributed to methylation in adjacent CTCF binding sites. A more detailed study of
congenital cases could be pertinent, considering the potential therapeutic benefit of inducing
contractions with methylating agents [49].
Conclusions
By comparing two tissue sources, our study has assessed the suitability of employing buccal
cells as an alternative tissue source of genetic material to carry out informative molecular anal-
yses in DM1, providing more accurate prognostic information, something that cannot be done
with other DM1 tissues due to the excessively large repeat size compared to blood and buccal
cells from saliva. Also, the data we present here provide new insights into the CTG tissue-spe-
cific mutational dynamics, a feature that is becoming increasingly important in terms of dis-
ease severity and progression, and as a target and marker for therapeutic intervention [16, 18,
27, 33, 42, 50, 51]. To achieve effective somatic therapy of the DM1 repeat expansion, careful
serial monitoring of therapeutic efficacy and detailed knowledge of the longitudinal CTG
mutational dynamics are essential. Clearly, non-invasive access to a readily accessible tissue in
which somatic mutational dynamics have been characterized will facilitate inclusion of a large
representative DM1 population with the least possible risk.
Although previous studies have already suggested the use of buccal cells for diagnostic pur-
poses in DM1 [52, 53], a detailed quantitative validation through single molecule SP-PCR in
order to evaluate the suitability of using saliva instead of blood, which is the standard source for
DNA testing in DM1, has not yet been performed in DM1 patients. Even though we found sub-
tle differences in the mutational dynamics in saliva and blood DNA, we provide evidence that
the PAL estimation through the SP-PCR assay using DNA obtained from saliva constitutes a
good surrogate tissue and less invasive approach for DM1 diagnosis. Our results are particularly
relevant given that in some of the main tissues affected in DM1 (such as skeletal muscle), deter-
mination of reliable estimates of the PAL is challenging due to the high levels of somatic mosai-
cism, which potentially compromises the quality of clinical correlations obtained. On the other
hand, tissues that have been proven to be especially stable (such as cerebellum) are not accessi-
ble, which limits their usefulness for performing routine molecular analysis. As demonstrated
here, the use of saliva DNA for these purposes, in combination with SP-PCR, constitutes a use-
ful alternative when the collection of blood samples is not feasible or problematic.
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S1 Fig. Box plots for the comparison of the modal allele length (A), the progenitor allele
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S2 Fig. A. Differences in the boundaries from allele distributions from blood and saliva
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two tissues. The interquartile ranges (IQR) are indicated as boxes; the medians and means are
represented by solid and dotted lines respectively subdividing the boxes; error bars indicating
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beyond the whiskers are outlying points. B. Polynomial relation of the degree of SI in blood
and saliva with the age at sampling and the logarithm of the progenitor allele length
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for the polynomial multiple regressions are shown as a mesh.
(PDF)
Acknowledgments
The authors would like to thank the myotonic dystrophy patients and their families for their
assistance. We also like to thank the members of the Krahe, Monckton and Morales labs.
Author Contributions
Conceptualization: Patricia Cuenca, Ralf Krahe, Darren G. Monckton, Fernando Morales.
Formal analysis: Eyleen Corrales, Melissa Va´squez, Baili Zhang, Carolina Santamarı´a-Ulloa,
Ralf Krahe, Darren G. Monckton, Fernando Morales.
Funding acquisition: Fernando Morales.
Methodology: Eyleen Corrales, Melissa Va´squez, Baili Zhang.
Project administration: Fernando Morales.
Writing – original draft: Eyleen Corrales.
Writing – review & editing: Eyleen Corrales, Ralf Krahe, Darren G. Monckton, Fernando
Morales.
Saliva and somatic instability in myotonic dystrophy type 1
PLOS ONE | https://doi.org/10.1371/journal.pone.0216407 May 2, 2019 14 / 17
References
1. Harper PS. Myotonic Dystrophy. 3rd ed. London: Harcourt Publisers Ltd; 2001.
2. Harper PS. Myotonic Dystrophy. 2nd ed: W B Saunders Company; 1989.
3. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myo-
tonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a pro-
tein kinase family member. Cell. 1992; 68: 799–808. PMID: 1310900
4. Fu YH, Pizzuti A, Fenwick RG, King J, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a
gene related to myotonic muscular dystrophy. Science. 1992; 255: 1256–1258. PMID: 1546326
5. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy
mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science. 1992; 255: 1253–
1255. PMID: 1546325
6. Ashizawa T, Dubel JR, Harati Y. Somatic instability of CTG repeat in myotonic dystrophy. Neurology.
1993; 43: 2674–2678. PMID: 8255475
7. Martorell L, Monckton DG, Gamez J, Baiget M. Complex patterns of male germline instability and
somatic mosaicism in myotonic dystrophy type 1. Eur J Hum Genet. 2000; 8: 423–430. https://doi.org/
10.1038/sj.ejhg.5200478 PMID: 10878662
8. Lavedan C, Hofmann-Radvanyi H, Shelbourne P, Rabes J-P, Duros C, Savoy D, et al. Myotonic dystro-
phy: size and sex dependent dynamics of CTG meiotic instability, and somatic mosaicism. Am J Hum
Genet. 1993; 52: 875–883. PMID: 8098180
9. Ashizawa T, Dubel JR, Dunne PW, Dunne CJ, Fu YH, Pizzuti A, et al. Anticipation in myotonic dystro-
phy. 2. Complex relationships between clinical findings and structure of the GCT repeat. Neurology.
1992; 42: 1877–1883. PMID: 1407566
10. Harley HG, Rundle SA, MacMillan JC, Myring J, Brook JD, Crow S, et al. Size of the unstable CTG
repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum
Genet. 1993; 52: 1164–1174. PMID: 8503448
11. Hunter A, Tsilfidis C, Mettler G, Jacob P, Mahadevan M, Surh L, et al. The correlation of age of onset
with CTG trinucleotide repeat amplification in myotonic dystrophy. J Med Genet. 1992; 29: 774–779.
PMID: 1453425
12. Marchini C, Lonigro R, Verriello L, Pellizzari L, Bergonzi P, Damante G. Correlations between individual
clinical manifestations and CTG repeat amplification in myotonic dystrophy. Clin Genet. 2000; 57: 74–
82. PMID: 10733240
13. Jansen G, Willems P, Coerwinkel M, Nillesen W, Smeets H, Vits L, et al. Gonosomal mosaicism in myo-
tonic dystrophy patients: involvement of mitotic events in (CTG)n repeat variation and selection against
extreme expansion in sperm. Am J Hum Genet. 1994; 54: 575–585. PMID: 8128954
14. Martorell L, Monckton DG, Gamez J, Johnson KJ, Gich I, de Munain AL, et al. Progression of somatic
CTG repeat length heterogeneity in the blood cells of myotonic dystrophy patients. Hum Mol Genet.
1998; 7: 307–312. PMID: 9425239
15. Monckton DG, Wong LJC, Ashizawa T, Caskey CT. Somatic mosaicism, germline expansions, germ-
line reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses.
Hum Mol Genet. 1995; 4: 1–8. PMID: 7711720
16. Morales F, Couto JM, Higham CF, Hogg G, Cuenca P, Braida C, et al. Somatic instability of the expanded
CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease
severity. Hum Mol Genet. 2012; 21: 3558–3567. https://doi.org/10.1093/hmg/dds185 PMID: 22595968
17. Wong L-JC, Ashizawa T, Monckton DG, Caskey CT, Richards CS. Somatic heterogeneity of the CTG
repeat in myotonic dystrophy is age and size dependent. Am J Hum Genet. 1995; 56: 114–122. PMID:
7825566
18. Morales F, Vasquez M, Santamaria C, Cuenca P, Corrales E, Monckton DG. A polymorphism in the
MSH3 mismatch repair gene is associated with the levels of somatic instability of the expanded CTG
repeat in the blood DNA of myotonic dystrophy type 1 patients. DNA Repair (Amst). 2016; 40: 57–66.
19. Anvret M, Ahlberg G, Grandell U, Hedberg B, Johnson K, Edstrom L. Larger expansions of the CTG
repeat in muscle compared to lymphocytes from patients with myotonic dystrophy. Hum Mol Genet.
1993; 2: 1397–1400. PMID: 8242063
20. Thornton CA, Johnson K, Moxley RT. Myotonic dystrophy patients have larger CTG expansions in skel-
etal muscle than in leukocytes. Ann Neurol. 1994; 35: 104–107. https://doi.org/10.1002/ana.410350116
PMID: 8285579
21. Zatz M, Passos-Bueno MR, Cerqueira A, Marie SK, Vainzof M, Pavanello RCM. Analysis of the CTG
repeat in skeletal muscle of young and adult myotonic dystrophy patients: when does the expansion
occur. Hum Mol Genet. 1995; 4: 401–406. PMID: 7795594
Saliva and somatic instability in myotonic dystrophy type 1
PLOS ONE | https://doi.org/10.1371/journal.pone.0216407 May 2, 2019 15 / 17
22. Buczko P, Zalewska A, Szarmach I. Saliva and oxidative stress in oral cavity and in some systemic dis-
orders. J Physiol Pharmacol. 2015; 66: 3–9. PMID: 25716960
23. Kaufman E, Lamster IB. The diagnostic applications of saliva—a review. Crit Rev Oral Biol Med. 2002;
13: 197–212. PMID: 12097361
24. Mikkonen JJ, Singh SP, Herrala M, Lappalainen R, Myllymaa S, Kullaa AM. Salivary metabolomics in
the diagnosis of oral cancer and periodontal diseases. J Periodontal Res. 2016; 51: 431–437. https://
doi.org/10.1111/jre.12327 PMID: 26446036
25. Kaczor-Urbanowicz KE, Martin Carreras-Presas C, Aro K, Tu M, Garcia-Godoy F, Wong DT. Saliva
diagnostics—Current views and directions. Exp Biol Med (Maywood). 2017; 242: 459–472.
26. Sun F, Reichenberger EJ. Saliva as a source of genomic DNA for genetic studies: review of current
methods and applications. Oral Health Dent Manag. 2014; 13: 217–222. PMID: 24984625
27. Braida C, Stefanatos RK, Adam B, Mahajan N, Smeets HJ, Niel F, et al. Variant CCG and GGC repeats
within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual
symptoms in some myotonic dystrophy type 1 patients. Hum Mol Genet. 2010; 19: 1399–1412. https://
doi.org/10.1093/hmg/ddq015 PMID: 20080938
28. Filippova GN, Thienes CP, Penn BH, Cho DH, Hu YJ, Moore JM, et al. CTCF-binding sites flank CTG/
CAG repeats and form a methylation- sensitive insulator at the DM1 locus. Nat Genet. 2001; 28: 335–
343. https://doi.org/10.1038/ng570 PMID: 11479593
29. Lopez Castel A, Nakamori M, Tome S, Chitayat D, Gourdon G, Thornton CA, et al. Expanded CTG
repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues.
Hum Mol Genet. 2011; 20: 1–15. https://doi.org/10.1093/hmg/ddq427 PMID: 21044947
30. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing
methylation analysis of CpG sites. Biotechniques. 2003; 35: 146–150. https://doi.org/10.2144/
03351md01 PMID: 12866414
31. Gibbs M, Collick A, Kelly RG, Jeffreys AJ. A tetranucleotide repeat mouse minisatellite displaying sub-
stantial somatic instability during early preimplantation development. Genomics. 1993; 17: 121–128.
https://doi.org/10.1006/geno.1993.1292 PMID: 8406443
32. Monckton DG, Coolbaugh MI, Ashizawa KT, Siciliano MJ, Caskey CT. Hypermutable myotonic dystro-
phy CTG repeats in transgenic mice. Nat Genet. 1997; 15: 193–196. https://doi.org/10.1038/ng0297-
193 PMID: 9020848
33. Musova Z, Mazanec R, Krepelova A, Ehler E, Vales J, Jaklova R, et al. Highly unstable sequence inter-
ruptions of the CTG repeat in the myotonic dystrophy gene. Am J Med Genet A. 2009; 149A: 1365–
1374. https://doi.org/10.1002/ajmg.a.32987 PMID: 19514047
34. Jaspert A, Fahsold R, Grehl H, Claus D. Myotonic Dystrophy—Correlation of clinical symptoms with the
size of the CTG trinucleotide repeat. J Neurol. 1995; 242: 99–104. PMID: 7707098
35. Redman JB, Fenwick RG, Fu YH, Pizzuti A, Caskey CT. Relationship between parental trinucleotide
GCT repeat length and severity of myotonic dystrophy in offspring. JAMA. 1993; 269: 1960–1965.
PMID: 8464127
36. Itoh K, Mitani M, Kawamoto K, Futamura N, Funakawa I, Jinnai K, et al. Neuropathology does not corre-
late with regional differences in the extent of expansion of CTG repeats in the brain with myotonic dys-
trophy type 1. Acta Histochem Cytochem. 2010; 43:149–156. https://doi.org/10.1267/ahc.10019 PMID:
21245981
37. Pesovic J, Peric S, Brkusanin M, Brajuskovic G, Rakocevic-Stojanovic V, Savic-Pavicevic D. Repeat
interruptions modify age at onset in myotonic dystrophy type 1 by stabilizing DMPK expansions in
somatic cells. Front Genet. 2018; 9: 601. https://doi.org/10.3389/fgene.2018.00601 PMID: 30546383
38. Martorell L, Johnson K, Boucher CA, Baiget M. Somatic instability of the myotonic dystrophy (CTG)n
repeat during human fetal development. Hum Mol Genet. 1997; 6: 877–880. PMID: 9175733
39. Hughes MW, Chuong CM. A mouthful of epithelial-mesenchymal interactions. J Invest Dermatol. 2003;
121: vii–viii.
40. Medvinsky A, Rybtsov S, Taoudi S. Embryonic origin of the adult hematopoietic system: advances and
questions. Development. 2011; 138: 1017–1031. https://doi.org/10.1242/dev.040998 PMID: 21343360
41. Higham CF, Morales F, Cobbold CA, Haydon DT, Monckton DG. High levels of somatic DNA diversity
at the myotonic dystrophy type 1 locus are driven by ultra-frequent expansion and contraction muta-
tions. Hum Mol Genet. 2012; 21: 2450–2463. https://doi.org/10.1093/hmg/dds059 PMID: 22367968
42. Larson E, Fyfe I, Morton AJ, Monckton DG. Age-, tissue- and length-dependent bidirectional somatic
CAG*CTG repeat instability in an allelic series of R6/2 Huntington disease mice. Neurobiol Dis. 2015;
76: 98–111. https://doi.org/10.1016/j.nbd.2015.01.004 PMID: 25662336
Saliva and somatic instability in myotonic dystrophy type 1
PLOS ONE | https://doi.org/10.1371/journal.pone.0216407 May 2, 2019 16 / 17
43. Lee JM, Pinto RM, Gillis T, St Claire JC, Wheeler VC. Quantification of age-dependent somatic CAG
repeat instability in Hdh CAG knock-in mice reveals different expansion dynamics in striatum and liver.
PLoS One. 2011; 6: e23647. https://doi.org/10.1371/journal.pone.0023647 PMID: 21897851
44. Higham CF, Monckton DG. Modelling and inference reveal nonlinear length-dependent suppression of
somatic instability for small disease associated alleles in myotonic dystrophy type 1 and Huntington dis-
ease. J R Soc Interface. 2013; 10: 20130605. https://doi.org/10.1098/rsif.2013.0605 PMID: 24047873
45. Libby RT, Hagerman KA, Pineda VV, Lau R, Cho DH, Baccam SL, et al. CTCF cis-regulates trinucleo-
tide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination.
PLoS Genet. 2008; 4: e1000257. https://doi.org/10.1371/journal.pgen.1000257 PMID: 19008940
46. Chung MY, Ranum LP, Duvick LA, Servadio A, Zoghbi HY, Orr HT. Evidence for a mechanism predis-
posing to intergenerational CAG repeat instability in spinocerebellar ataxia type I. Nat Genet. 1993; 5:
254–258. https://doi.org/10.1038/ng1193-254 PMID: 8275090
47. Barbe L, Lanni S, Lopez-Castel A, Franck S, Spits C, Keymolen K, et al. CpG methylation, a parent-of-
origin effect for maternal-biased transmission of congenital myotonic dystrophy. Am J Hum Genet.
2017; 100: 488–505. https://doi.org/10.1016/j.ajhg.2017.01.033 PMID: 28257691
48. Steinbach P, Glaser D, Vogel W, Wolf M, Schwemmle S. The DMPK gene of severely affected myotonic
dystrophy patients is hypermethylated proximal to the largely expanded CTG repeat. Am J Hum Genet.
1998; 62: 278–285. https://doi.org/10.1086/301711 PMID: 9463318
49. Gomes-Pereira M, Monckton DG. Chemical modifiers of unstable expanded simple sequence repeats:
What goes up, could come down. Mutat Res. 2006; 598: 15–34. https://doi.org/10.1016/j.mrfmmm.
2006.01.011 PMID: 16500684
50. Tome S, Dandelot E, Dogan C, Bertrand A, Genevieve D, Pereon Y, et al. Unusual association of a
unique CAG interruption in 5’ of DM1 CTG repeats with intergenerational contractions and low somatic
mosaicism. Hum Mutat. 2018; 39: 970–982. https://doi.org/10.1002/humu.23531 PMID: 29664219
51. Cinesi C, Aeschbach L, Yang B, Dion V. Contracting CAG/CTG repeats using the CRISPR-Cas9 nick-
ase. Nat Commun. 2016; 7: 13272. https://doi.org/10.1038/ncomms13272 PMID: 27827362
52. Holt I, Quinlivan R, Couto J, Monckton DG, Morris G. The use of buccal cells for rapid diagnosis of myo-
tonic dystrophy type 1. Translational Neuroscience. 2010; 1: 195–199.
53. Jou SB, Lin HM, Pan H, Chiu YL, Li SY, Lee CC, et al. Delineation of CTG repeats and clinical features
in a Taiwanese myotonic dystrophy family. Proc Natl Sci Counc Repub China B. 2001; 25: 40–44.
PMID: 11254171
Saliva and somatic instability in myotonic dystrophy type 1
PLOS ONE | https://doi.org/10.1371/journal.pone.0216407 May 2, 2019 17 / 17
